Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pharmacokinetic study Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants

NCT04474210
View directory record Official record
Conditions
Renal Insufficiency
Interventions
JNJ-56136379
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

NCT00743860
View directory record Official record
Conditions
Atherosclerosis
Interventions
darapladib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 18, 2026, 1:14 AM EDT
Terminated Phase 1 Interventional

SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy

NCT00936520
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Pars Plana Vitrectomy
Interventions
SAR 1118 0.1%, SAR 1118 1.0%, SAR 1118 5.0%
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

NCT01873339
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Midazolam
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

NCT00532844
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

NCT02684799
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Omeprazole, Famotidine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 18, 2026, 1:14 AM EDT
Withdrawn Phase 1 Interventional

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment

NCT01632436
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Pixantrone
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

NCT02000934
View directory record Official record
Conditions
Advanced Solid Tumor and Lymphoma Malignancies
Interventions
TAK-659
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
5
States / cities
Sarasota, Florida • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 4 Interventional Results available

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

NCT02403830
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Methylnaltrexone, Placebo, Morphine, Ticagrelor
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 18, 2026, 1:14 AM EDT
Active, not recruiting Phase 2 Interventional

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

NCT06293365
View directory record Official record
Conditions
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions
VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
17
States / cities
Anniston, Alabama • Fullerton, California • La Palma, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 3 Interventional

Study of Oral Morphine Sulfate Administration in Pediatric Subjects

NCT03429400
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Morphine Sulfate
Drug
Lead sponsor
West-Ward Pharmaceutical
Industry
Eligibility
2 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sheffield, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

NCT02001571
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
40 Years to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss

NCT04462198
View directory record Official record
Conditions
Sensorineural Hearing Loss
Interventions
PIPE-505, Placebo
Drug
Lead sponsor
Contineum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Torrance, California • Boca Raton, Florida • New Albany, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First In Human Study Of PF-00184562 In Healthy Volunteers

NCT00150215
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-00184562, Olanzapine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2006 · Synced Oct 18, 2026, 1:14 AM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

NCT02163915
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
TAK-137, TAK-137 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Marlton, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus

NCT00957268
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Alogliptin
Drug
Lead sponsor
Takeda
Industry
Eligibility
10 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Miami, Florida • Pineallas Park, Florida • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.

NCT00989625
View directory record Official record
Conditions
Migraine Disorders
Interventions
This is a pharmacokinetic study (Treximet)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Wichita, Kansas • Louisville, Kentucky • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

A Safety and PK Study of IV Eravacycline

NCT03696550
View directory record Official record
Conditions
Bacterial Infections
Interventions
Eravacycline (TP-434)
Drug
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Industry
Eligibility
8 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

NCT00183859
View directory record Official record
Conditions
Adenocarcinoma, Gastric Cancer
Interventions
irinotecan
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

High-Dose Cytarabine Plus Deoxycytidine in Treating With Acute Myelogenous Leukemia or Other Hematologic Malignancies

NCT00002818
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
cytarabine, deoxycytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

NCT00816660
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII), Marketed plasma-derived VWF/FVIII concentrate
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 18, 2026, 1:14 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Children With COVID-19

NCT05074420
View directory record Official record
Conditions
Covid19, Corona Virus Infection
Interventions
Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Orlando, Florida • Detroit, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Not yet recruiting Not applicable Interventional

Local Antibiotic Concentrations With Tissue Expanders in Breast Reconstruction

NCT07339215
View directory record Official record
Conditions
Tissue Expander Based Breast Reconstruction
Interventions
Antibiotic loaded calcium sulfate beads, Polymethylmethacrylate antibiotic disc
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 18, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

NCT03315689
View directory record Official record
Conditions
Alopecia Universalis (AU), Alopecia Totalis (AT)
Interventions
Vehicle, ATI-50002
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 18, 2026, 1:14 AM EDT